Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryBiotechnology
SectorMedical
Phone650-556-9300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$394.11 million
Profitability
Miscellaneous
Employees829
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Genomic Health (NASDAQ:GHDX) Frequently Asked Questions
What is Genomic Health's stock symbol?
Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."
How were Genomic Health's earnings last quarter?
Genomic Health, Inc. (NASDAQ:GHDX) issued its earnings results on Monday, July, 29th. The medical research company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.07. The medical research company had revenue of $114.14 million for the quarter, compared to the consensus estimate of $110.78 million. Genomic Health had a return on equity of 19.51% and a net margin of 11.69%. The company's revenue was up 19.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.23 earnings per share. View Genomic Health's Earnings History.
When is Genomic Health's next earnings date?
What guidance has Genomic Health issued on next quarter's earnings?
Genomic Health updated its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $1.44-1.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.44. The company issued revenue guidance of $448-452 million, compared to the consensus revenue estimate of $445.06 million.
What price target have analysts set for GHDX?
9 brokerages have issued 1 year target prices for Genomic Health's stock. Their predictions range from $55.00 to $72.00. On average, they anticipate Genomic Health's share price to reach $68.67 in the next twelve months. This suggests that the stock has a possible downside of 3.6%. View Analyst Price Targets for Genomic Health.
What is the consensus analysts' recommendation for Genomic Health?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health.
What are Wall Street analysts saying about Genomic Health stock?
Here are some recent quotes from research analysts about Genomic Health stock:
- 1. According to Zacks Investment Research, "Over the past year, Genomic Health has been outperforming its industry. The company is registering robust top-line growth banking on solid performance in the United States and internationally. In the last-reported quarter, breast cancer revenues were strong driven by increased Oncotype DX Breast Recurrence Score test usage globally which is amplifying on favorable results from the landmark TAILORx trial. Within the prostate cancer space, the company is seeing robust improvement in volume as the Oncotype DX GPS test consistently leads the market in low- and intermediate-risk prostate cancer test adoption. However, the company’s sole reliance on the Breast Oncotype DX test is a concern. Moreover, the company continues to face fierce competition for Oncotype DX tests." (7/31/2019)
- 2. Canaccord Genuity analysts commented, "We are also lowering our price target from $77 to the deal price of $72. Our prior $77 PT used a 6.7x multiple on our 2021 revenue estimate of $540M. We note that our peer group (as of today) is trading at 6.7x our 2020 revenue estimates." (7/30/2019)
Has Genomic Health been receiving favorable news coverage?
News stories about GHDX stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genomic Health earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Genomic Health.
Are investors shorting Genomic Health?
Genomic Health saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 1,380,000 shares, a decline of 25.4% from the August 30th total of 1,850,000 shares. Based on an average trading volume of 636,800 shares, the days-to-cover ratio is presently 2.2 days. Approximately 3.7% of the company's shares are short sold. View Genomic Health's Current Options Chain.
Who are some of Genomic Health's key competitors?
Some companies that are related to Genomic Health include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Personalis (PSNL), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN) and PotNetwork (POTN).
What other stocks do shareholders of Genomic Health own?
Who are Genomic Health's key executives?
Genomic Health's management team includes the folowing people:
- Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 60)
- Dr. Steven Shak, Co-Founder & Chief Scientific Officer (Age 68)
- Mr. G. Bradley Cole, Chief Financial Officer (Age 63)
- Dr. Frederic G. Pla, Chief Operating Officer (Age 60)
- Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 56)
Who are Genomic Health's major shareholders?
Genomic Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include Havens Advisors LLC (0.08%), State of Alaska Department of Revenue (0.04%) and Everence Capital Management Inc. (0.01%). Company insiders that own Genomic Health stock include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kim Mceachron, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health.
Which major investors are buying Genomic Health stock?
How do I buy shares of Genomic Health?
Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genomic Health's stock price today?
One share of GHDX stock can currently be purchased for approximately $71.22.
How big of a company is Genomic Health?
Genomic Health has a market capitalization of $2.66 billion and generates $394.11 million in revenue each year. The medical research company earns $25.68 million in net income (profit) each year or $1.05 on an earnings per share basis. Genomic Health employs 829 workers across the globe.View Additional Information About Genomic Health.
What is Genomic Health's official website?
How can I contact Genomic Health?
Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]
MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
